Tisiparatide provides better glycemic control and weight loss compared with semaglutide and insulin

Intype 2 diabetes (T2D),tirzepatide/tirpotide (Tirzepatide) has longer sustained glycemic control than placebo or an active comparator (type 2 diabetes). These findings were derived from post hoc analyzes and published articles. SURPASS Studies 1 to 5 were Phase 3 clinical trials in which researchers compared 5, 10, or 15 mg of tirsiparatide with placebo, 1 mg of semaglutide, and insulin Efficacy of degludec (insulin degludec) or insulin glargine over 40 or 52 weeks.

In this post hoc analysis, researchers evaluatedThe time that patients with T2D (N=6246) maintained glycated hemoglobin (HbA1c) below 7.0% while receiving 5 mg of tissiparatide (N=1393), 10 mg of tissiparatide (N=1394), 15 mg of tissiparatide (N=14 02), placebo (N=232), 1 mg of semaglutide (N=468), insulin glargine (N=359), or insulin glargine (N=998) and a minimum 5% weight loss from baseline.

In participants with T2D, treatment with 5, 10, and 15 mg of tilsiparatide was associated with HbA1c <7.0% (53mmol/mol) and HbA1c≤6.5% (48mmol) compared with placebo and active controls. /mol") and sustained weight loss of ≥5% were associated with significantly longer duration of glycemic control. The mean age of the study population was between 54 and 64 years, and T2D duration between 5 and 13 years. Across all trials, 38% to 53% were female and 36% to 91% were white.

Patients receiving tilsiparatide maintainedHbA1c below 7.0% longer than the other treatment groups (P<0.001). In the 40-week study, the median time to treatment with HbA1c below 7.0% was 32 weeks with tilsiparatide, 28 weeks with semaglutide, and 0 weeks with placebo. In the 52-week study, the median time to treatment with HbA1c below 7.0% was 40 to 44 weeks with tilsiparatide, compared with 32 weeks with insulin degludec and 12 weeks with insulin glargine.

Patients who received tilsiparatide lost 5% or more of their body weight for longer than those in other treatment groups (P<0.001). In studies lasting 40 weeks, the median time to weight loss of 5% or more was 8 to 24 weeks with tisipatin compared with 10 weeks with semaglutide and 0 weeks with placebo. In studies that lasted 52 weeks, the median time to weight loss of 5% or more with tilsiparatide was 28 to 40 weeks compared with 0 weeks of insulin treatment.

Tisiparatide was also associated with longer duration of maintenance of glycemic control and weight loss goals (P<0.001). The composite endpoint was achieved in 66% to 85% of tsiparatide receptors and 54% of semaglutide receptors. Similar trends were observed with HbA1c glycemic control goals of 6.5% or less. This study was exploratory in nature and not hypothesis-driven, limiting the power of the results.

Therefore Conclusions: In this participant-level exploratory analysis of the SUPPORSE clinical trial [Project], compared with placebo and an active control group of T2D participants, the use of 5, 10, and 1 Treatment with 5 mg tilsiparatide resulted in significantly longer duration of [glycemic] control, with HbA1c<7.0% (53mmol/mol), HbA1c≤6.5% (48mmol/mol), and sustained weight loss ≥5%.

Reference materials:https://www.endocrinologyadvisor.com/news/tirzepatide-yields-superior-glycemic-control-weight-loss-outcomes/